Jing-Tao Lu1, Ying Cai2, Feng Chen3, Wei-Wei Jia4, Zhe-Yi Hu5, Yuan-Sheng Zhao6. 1. Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA. 2. Department of Physiology, Michigan State University, East Lansing, MI, USA. 3. School of Pharmacy, Hainan Medical University, Haikou, China. 4. Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China. 5. Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave., Memphis, TN, 38163, USA. zhu13@uthsc.edu. 6. Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, 1428 Madison Ave, New York, NY, 10029, USA. yuansheng.zhao@gmail.com.
Abstract
BACKGROUND AND OBJECTIVE: Amiodarone (AMD) is one of the most effective drugs for rhythm control of atrial fibrillation. The use of AMD is also associated with adverse effects in multiple tissues. Both the parent compound and its major metabolite desethylamiodarone (DEA) contribute to the drug's therapeutic and toxic action. The present study aimed to build a whole-body physiologically based pharmacokinetic (PBPK) model for AMD and DEA in rats. METHODS: Pharmacokinetic data from multiple studies were collected. Some of the data were pooled together to develop the PBPK model; others were used to evaluate the model. Development of the model also involved in vitro to in vivo extrapolation based on in vitro metabolism data. RESULTS: The final model consisted of 11 tissue compartments, including therapeutic target organs and those to which AMD and DEA may be harmful. Model simulations were in good agreement with the observed time courses of the drug-metabolite pair in tissues, under various dosing scenarios. The key pharmacokinetic properties of AMD, such as extensive tissue distribution, substantial storage in the fat tissue, and long half-lives in many tissues, were closely reflected. CONCLUSION: The developed PBPK model can be regarded as the first step towards a PBPK-pharmacodynamic model that can used to mechanistically evaluate and explain the high adverse event rate and potentially to determine which factors are the primary drives for experiencing an adverse event.
BACKGROUND AND OBJECTIVE:Amiodarone (AMD) is one of the most effective drugs for rhythm control of atrial fibrillation. The use of AMD is also associated with adverse effects in multiple tissues. Both the parent compound and its major metabolite desethylamiodarone (DEA) contribute to the drug's therapeutic and toxic action. The present study aimed to build a whole-body physiologically based pharmacokinetic (PBPK) model for AMD and DEA in rats. METHODS: Pharmacokinetic data from multiple studies were collected. Some of the data were pooled together to develop the PBPK model; others were used to evaluate the model. Development of the model also involved in vitro to in vivo extrapolation based on in vitro metabolism data. RESULTS: The final model consisted of 11 tissue compartments, including therapeutic target organs and those to which AMD and DEA may be harmful. Model simulations were in good agreement with the observed time courses of the drug-metabolite pair in tissues, under various dosing scenarios. The key pharmacokinetic properties of AMD, such as extensive tissue distribution, substantial storage in the fat tissue, and long half-lives in many tissues, were closely reflected. CONCLUSION: The developed PBPK model can be regarded as the first step towards a PBPK-pharmacodynamic model that can used to mechanistically evaluate and explain the high adverse event rate and potentially to determine which factors are the primary drives for experiencing an adverse event.
Authors: Guy M L Meno-Tetang; Hongshan Li; Suzette Mis; Nancy Pyszczynski; Peter Heining; Philip Lowe; William J Jusko Journal: Drug Metab Dispos Date: 2006-06-02 Impact factor: 3.922
Authors: J H Lewis; R C Ranard; A Caruso; L K Jackson; F Mullick; K G Ishak; L B Seeff; H J Zimmerman Journal: Hepatology Date: 1989-05 Impact factor: 17.425
Authors: Engi Abdelhady Algharably; Emma Di Consiglio; Emanuela Testai; Francesca Pistollato; Hans Mielke; Ursula Gundert-Remy Journal: Front Toxicol Date: 2022-07-18